Close Menu

NEW YORK – Liquid biopsy developer Angle said on Monday that it has submitted a full de novo submission to the US Food and Drug Administration for its Parsortix system for use with metastatic breast cancer (MBC) patients.

The UK-based firm said the submission provides a data package that highlights Parsortix's ability to harvest circulating tumor cells (CTCs) from MBC patient blood samples for downstream analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.

The New York Times reports that developers in New York City are increasingly interested in life science spaces.

A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.

In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.